Veeva Systems introduced the Veeva Study Builder Agent, an AI tool that automates the configuration of clinical study data collection and quality systems based on existing organizational standards and CDISC models. This innovation aims to accelerate study setup, ensure consistency, and produce audit-ready results by minimizing deviations from standards. The agent will be available to early adopters in December 2026 as part of Veeva's EDC system without requiring additional licenses. This development supports Veeva's goal to simplify and standardize clinical trials, benefiting life sciences companies by improving efficiency and data quality.
Veeva Systems shares are trading at USD 269.26 on Pluang, showing a slight decline of 0.55% in the last day. As of Sep 24, 2026 18:21 WIB, the stock's market cap stands at $43.84 billion with a balanced order activity of 48% sell and 52% buy.
Veeva Systems announced that Vault CRM has secured commitments from 14 of the top 20 biopharma companies, including recent additions like Amgen, Biogen, Eli Lilly, and Regeneron. With over 190 live customers, Vault CRM offers advanced AI-driven featu...
Veeva Systems announced the Falcon Router, a new tool designed to quickly and accurately route safety adverse event reports, product quality complaints, and medical inquiries to the appropriate teams in biopharma companies. This automation reduces ma...
